Pulmonx Corp

The company is a commercial-stage medical technology company that offers a minimally invasive treatment for patients with severe emphysema, a type of chronic obstructive pulmonary disease (COPD). Its solution includes the Zephyr Endobronchial Valve ("Zephyr Valve"), the Chartis Pulmonary Assessment System ("Chartis System"), and the LungTraX Platform. This system is designed for severe emphysema patients who remain symptomatic despite medical management and are unwilling or ineligible for surgery. The Zephyr Valve received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA) in 2018 and is now commercially available globally. The company has secured reimbursement in major markets across North America, Europe, and Asia Pacific, and the Zephyr Valve is included in worldwide COPD treatment guidelines. Over 150 scientific articles have been published on the Zephyr Valve's clinical benefits, including multiple meta-analyses, review articles, cost-effectiveness analyses, and risk-benefit analyses. Randomized controlled clinical trials showed statistically significant improvements in lung function, exercise capacity, and quality of life compared to medical management alone. Independent studies also demonstrated increases in the BODE Index, associated with long-term survival benefits. The company also manufactures the AeriSeal System, a synthetic polymer foam designed to close collateral air channels in a target lung lobe, converting it to having little to no collateral ventilation (CV-). The AeriSeal System has received a "Breakthrough Device" designation from the FDA and a Certificate of Conformity ("CE Mark") in Europe, but it is not FDA-approved or approved for commercial sale in the United States.